Newbridge Expands its Presence in the Biotech Industry
FT. LAUDERDALE, Fla., Feb. 17 /PRNewswire/ -- Newbridge Securities Corporation ("Newbridge"), a full-service securities broker-dealer and investment bank, is proud to announce the formation of the Newbridge BioVentures Division ("NBV"). NBV is dedicated to providing investment banking services for the biotech industry and related investment opportunities for institutional and sophisticated individual investors.
We are pleased to announce Christopher Carra as the Managing Director of NBV. Mr. Carra has been a registered representative in the securities industry for over 16 years, primarily focused in the biotech sector. Mr. Carra has been involved in several private placements and initial public offerings for biotech companies, and is a founding member of NBV. Prior to joining Newbridge in 2005, Mr. Carra worked at several private-client focused firms, most recently Oppenheimer & Co., where he worked from 2000-2005 as a senior vice president.
Please visit the BioVentures website; it can be accessed through www.newbridgesecurities.com or www.investbiopharma.com.
"We are extremely excited to add NBV as a focus to our already diversified suite of businesses," said Guy S. Amico, Newbridge's president. "In addition, having powerful advisors, such as Dr. David Sherris, Ph.D., on the Scientific Advisory board will lend top-level credibility and research to enhance our success rate for our Institutional and Private Client Group clients."
Newbridge Securities Corporation provides full service securities brokerage and investment banking services to a broad based group of individuals and corporate clients. Comprised of a committed and experienced team of financial service professionals, we seek to empower our clients to build and preserve wealth by providing superior financial services and products.
For more information on NBV, contact Christopher Cara at 561.391.1220 (email at firstname.lastname@example.org) or visit our website at www.newbridgesecurities.com.
CONTACT: Christopher Cara of Newbridge Securities Corporation,
Web site: http://www.investbiopharma.com/